Masimo Corporation (MASI) on Decifer

Why it ranks here

• It earns strong returns on the money it puts to work, around 18% and those returns have been improving.
• Revenue is expected to grow about 8% a year, profits grew 51% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Returns near 18% and profits up 51% in a leading healthcare sector are solid, but with no role in the standing worldview there is no funded demand wave to force a re-rate.

The current read

The evidence on MASI lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Robotic & Minimally-Invasive Intervention: Clinical and economic evidence favoring minimally invasive robotic and thrombectomy procedures is shifting procedure volumes and capital equipment budgets toward advanced interventional platforms.

Read the full MASI research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.